Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.54 |
| ▸ | GABRD | O14764 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.54 |
| ▸ | GABRE | P78334 | 2/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.54 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.54 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.54 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.44 |
| ▸ | KDM4A | O75164 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751466 | 0.88 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1752703 | 0.88 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1752252 | 0.88 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29282935 | 0.87 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11559068 | 0.85 | TSHR (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18087340 | 0.84 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29282934 | 0.83 | FOLH1 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10961589 | 0.82 | — | — | |
| SCHEMBL27820216 | 0.81 | TSHR (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6695222 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063413-A | Cabazitaxel triglyceride prodrug, and preparation method and application thereof | 沈阳药科大学 | 2024-05-24 | — | — | CN | claimed |
| US-5342724-A | Preparing polyester from diol and diacid wherein one of the monomers has disulfuide linkage, reacting polyester with unsaturated monomer to create addition polymer blocks linked by sulfide group from dislufide linkage | EASTMAN KODAK COMPANY (US) | 1994-08-30 | — | — | US | claimed |
| WO-2024179213-A1 | CHOPPED FIBER COMPOSITE MATERIAL AND PREPARATION METHOD THEREFOR, AND TELEVISION REAR SHELL AND PREPARATION METHOD THEREFOR | 惠州视维新技术有限公司 | 2024-09-06 | — | — | WO | disclosed |
| CN-118063413-A | Cabazitaxel triglyceride prodrug, and preparation method and application thereof | 沈阳药科大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-114891320-B | Epoxy resin/chopped glass fiber composite material and preparation method thereof | 重庆国际复合材料股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-114891320-A | Epoxy resin/chopped glass fiber composite material and preparation method thereof | 重庆国际复合材料股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-9518017-B2 | Purification of intermediates used in the preparation of heterobifunctional linkers | IMMUNOGEN, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518017-B2 | Purification of intermediates used in the preparation of heterobifunctional linkers | IMMUNOGEN, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160137604-A1 | PURIFICATION OF INTERMEDIATES USED IN THE PREPARATION OF HETEROBIFUNCTIONAL LINKERS | IMMUNOGEN, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137604-A1 | PURIFICATION OF INTERMEDIATES USED IN THE PREPARATION OF HETEROBIFUNCTIONAL LINKERS | IMMUNOGEN, INC. | 2016-05-19 | — | — | US | disclosed |
| US-5342724-A | Preparing polyester from diol and diacid wherein one of the monomers has disulfuide linkage, reacting polyester with unsaturated monomer to create addition polymer blocks linked by sulfide group from dislufide linkage | EASTMAN KODAK COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| US-4141734-A | SUBSTITUTED ORGANIC DI- OR TRISULFIDE ANTIDEPOSIT AGENTS | CIBA-GEIBY AG (CH) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137604-A1 | PURIFICATION OF INTERMEDIATES USED IN THE PREPARATION OF HETEROBIFUNCTIONAL LINKERS | MCM5, SMCHD1, BMP2 | GABRP 2261/4885GABRD 1812/4885GABRA1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.